[Trastuzumab Deruxtecan for EGFR-mutant Lung Adenocarcinoma with Acquired High-level HER2 Amplification: A Case Report] [0.03%]
[一种携带高倍HER2扩增的EGFR突变型肺腺癌的小鼠模型对曲妥珠单抗deruxtecan的反应：病例报告]
Xiaoxiao Ge,Hefeng Chen,Shaohua Cui
Xiaoxiao Ge
Trastuzumab deruxtecan is a newly developed antibody-drug conjugate (ADC) designed to overcome human epidermal growth factor receptor 2 (HER2) aberrations. Studies have confirmed that Trastuzumab deruxtecan yields promising efficacy with a ...
[Research Advances in Obstructive Sleep Apnea and Lung Cancer Comorbidity] [0.03%]
阻塞性睡眠呼吸暂停与肺癌并存的研究进展
He Cao,Shanshan Yang,Wenjia Sun et al.
He Cao et al.
Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder characterized by recurrent upper airway collapse and apnea during sleep, resulting in intermittent hypoxia, oxidative stress, and systemic inflammation, and is close...
[Neuroregulatory Mechanisms of Lung Cancer Progression and Clinical Treatment Challenges from the Perspective of Cancer Neuroscience] [0.03%]
从癌症神经科学角度探究肺癌进展的神经调控机制及临床治疗挑战
Na Wang,Bo Zhang,Lihan Shang et al.
Na Wang et al.
Lung cancer is the leading cause of cancer morbidity and mortality worldwide. A highly complex bidirectional regulatory relationship exists between lung cancer progression and the nervous system. The nervous system is believed to play a piv...
[Role of Gut Mycobiome in Lung Cancer Immunotherapy: Mechanisms, Challenges and Translational Prospects] [0.03%]
肠道真菌群与肺癌免疫治疗的作用：机制、挑战及转化前景
Xinyi Wang,Yu Sun,Min Liu et al.
Xinyi Wang et al.
Lung cancer is one of the most common malignancies with the highest morbidity and mortality worldwide. Immune checkpoint inhibitors (ICIs) have significantly improved the prognosis of patients with advanced lung cancer, but more than half o...
[Heterogeneity of Response to PD-1/PD-L1 Inhibitors in Elderly Patients with Advanced NSCLC under the Background of Immunosenescence and Intervention Strategies] [0.03%]
[免疫衰老背景下老年晚期肺腺癌患者PD-1/PD-L1抑制剂治疗的异质性和干预策略]
Yurong Huang,Yuan Wang,Aojiao Wei et al.
Yurong Huang et al.
The proportion of elderly patients with advanced non-small cell lung cancer (NSCLC) is on the rise. While programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors have revolutionized the management of advanced NSCLC an...
[Clinicopathological, Genomic Characteristics and Prognostic Analysis in 18 Cases of SMARCA4-deficient or SMARCA4-mutated Pulmonary Tumors] [0.03%]
SMARCA4缺陷或SMARCA4突变肺肿瘤的临床病理、基因组特点及预后分析(18例报告)
Chang Liu,Jing Yang,Fanlu Meng et al.
Chang Liu et al.
Background: The diagnosis of SMARCA4-altered pulmonary tumors primarily relies on the detection of protein loss by immunohistochemistry (IHC). However, the concordance between IHC and genetic testing results, as well as t...
[Preliminary Analysis of Tumor Immune Microenvironment Characteristics in Lung Squamous Cell Carcinoma after Neoadjuvant Immunochemotherapy Based on Single-cell Transcriptomics] [0.03%]
基于单细胞转录组的 neo-CIS治疗后肺鳞癌肿瘤免疫微环境特征初步分析
Guannan Wang,Yanan Wang,Jinghao Liu et al.
Guannan Wang et al.
Background: Neoadjuvant immunochemotherapy has emerged as an important treatment strategy for non-small cell lung cancer (NSCLC); however, substantial heterogeneity in therapeutic response persists among patients. Current...
[Value of CD4+/CD8+ Ratio Combined with nCD64 Index in Bronchoalveolar Lavage Fluid for Differential Diagnosis of Lung Cancer and Non-lung Cancer Diseases] [0.03%]
支气管肺泡灌洗液中CD4+/CD8+联合nCD64指数鉴别诊断肺癌和非肺癌疾病的临床价值分析
Xuexue Wu,Chan Yang,Lili Jiang
Xuexue Wu
Background: Distinguishing lung cancer from pulmonary infection and interstitial lung disease (ILD) remains challenging. This study aimed to evaluate the diagnostic value of T lymphocyte subsets and neutrophil CD64 (nCD64...
[New Landscape in the Treatment of Limited-stage Small Cell Lung Cancer: From Conventional Chemoradiotherapy to Latest Advances in Precision Medicine] [0.03%]
限局期小细胞肺癌治疗新景观：从常规放化疗到精准医学最新进展
Jingwen Han,Keyao Dai,Zixi Meng et al.
Jingwen Han et al.
Limited-stage small cell lung cancer (LS-SCLC) is a highly aggressive malignancy with a poor prognosis. For a long time, the standard first-line treatment has been Etoposide plus Platinum-based chemotherapy combined with concurrent thoracic...
[Advances in Lactate Metabolic Reprogramming in Non-small Cell Lung Cancer] [0.03%]
非小细胞肺癌乳酸代谢重编程研究进展
Jun Zhou,Liuling Ge,Jingting Jiang
Jun Zhou
Non-small cell lung cancer (NSCLC) is characterized by high incidence and mortality, with a low five-year survival rate. Lactate metabolism plays a central role in the metabolic reprogramming of NSCLC. Beyond serving as the end-product of g...